20th Jan 2021 21:32
Amryt Pharma PLC - biopharmaceutical company - Says the National Institute for Health & Care Excellence has approved Myalepta for reimbursement in England and Wales as an adjunct to diet as replacement therapy for the treatment of leptin deficiency in patients with congenital or acquired general lipodystrophy in adults and children two years of age and above and familial or acquired partial lipodystrophy in adults and children 12 years of age and above. Myalepta received marketing authorisation from the European Medicines Agency in 2018.
Current stock price: 206.00 pence, up 5.6% on Wednesday
Year-to-date change: up 6.2%
By Evelina Grecenko; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
AMYT.L